Due to the efficacy of PD-1 inhibitors in relapsed cHL, (Table 1) several studies were initiated that combined nivolumab or pembrolizumab with other agents as second-line therapy, aiming to enhance patients’ CR rates before consolidative autologous stem-cell transplant (ASCT). This evidence concerns the gene PDCD1 and classic Hodgkin lymphoma.